Welcome!

News Feed Item

Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/703975/Coronary-Arteriosclerosis-Global-Clinical-Trials-Review-H2-2014.html

Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014" provides data on the Coronary Arteriosclerosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Coronary Arteriosclerosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Coronary Arteriosclerosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Coronary Arteriosclerosis 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Coronary Arteriosclerosis 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Coronary Arteriosclerosis Therapeutics Clinical Trials 29
Prominent Drugs 30
Clinical Trial Profiles 31
Clinical Trial Overview of Top Companies 31
Pfizer Inc. 31
Clinical Trial Overview of Pfizer Inc. 31
Merck & Co., Inc. 32
Clinical Trial Overview of Merck & Co., Inc. 32
Eli Lilly and Company 33
Clinical Trial Overview of Eli Lilly and Company 33
Cytori Therapeutics, Inc. 34
Clinical Trial Overview of Cytori Therapeutics, Inc. 34
C. H. Boehringer Sohn AG & Co. KG 35
Clinical Trial Overview of C. H. Boehringer Sohn AG & Co. KG 35
AstraZeneca PLC 36
Clinical Trial Overview of AstraZeneca PLC 36
MDDX LLC 37
Clinical Trial Overview of MDDX LLC 37
Innovaderm Research Inc. 38
Clinical Trial Overview of Innovaderm Research Inc. 38
CardioVascular BioTherapeutics, Inc. 39
Clinical Trial Overview of CardioVascular BioTherapeutics, Inc. 39
Avant Immunotherapeutics, Inc 40
Clinical Trial Overview of Avant Immunotherapeutics, Inc 40
Clinical Trial Overview of Top Institutes / Government 41
National Heart, Lung, and Blood Institute 41
Clinical Trial Overview of National Heart, Lung, and Blood Institute 41
Providence VA Medical Center 42
Clinical Trial Overview of Providence VA Medical Center 42
National Taiwan University Hospital 43
Clinical Trial Overview of National Taiwan University Hospital 43
Seoul National University Hospital 44
Clinical Trial Overview of Seoul National University Hospital 44
Rigshospitalet 45
Clinical Trial Overview of Rigshospitalet 45
University of Ottawa Heart Institute 46
Clinical Trial Overview of University of Ottawa Heart Institute 46
University of California, San Diego 47
Clinical Trial Overview of University of California, San Diego 47
University of Minnesota 48
Clinical Trial Overview of University of Minnesota 48
Massachusetts General Hospital 49
Clinical Trial Overview of Massachusetts General Hospital 49
U.S. Department of Veterans Affairs 50
Clinical Trial Overview of U.S. Department of Veterans Affairs 50
Five Key Clinical Profiles 51
Appendix 81
Abbreviations 81
Definitions 81
Research Methodology 82
Secondary Research 82
About GlobalData 83
Contact Us 83
Disclaimer 83
Source 83

List of Tables
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Region, 2014* 7
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Coronary Arteriosclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Coronary Arteriosclerosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Coronary Arteriosclerosis Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Coronary Arteriosclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Coronary Arteriosclerosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 15
Coronary Arteriosclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Coronary Arteriosclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 18
Coronary Arteriosclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Coronary Arteriosclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Coronary Arteriosclerosis Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Coronary Arteriosclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 31
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 32
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 33
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Cytori Therapeutics, Inc., 2014* 34
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by C. H. Boehringer Sohn AG & Co. KG, 2014* 35
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 36
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by MDDX LLC, 2014* 37
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Innovaderm Research Inc., 2014* 38
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by CardioVascular BioTherapeutics, Inc., 2014* 39
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Avant Immunotherapeutics, Inc, 2014* 40
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Heart, Lung, and Blood Institute, 2014* 41
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Providence VA Medical Center, 2014* 42
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Taiwan University Hospital, 2014* 43
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Seoul National University Hospital, 2014* 44
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Rigshospitalet, 2014* 45
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Ottawa Heart Institute, 2014* 46
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Diego, 2014* 47
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Minnesota, 2014* 48
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014* 49
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by U.S. Department of Veterans Affairs, 2014* 50

List of Figures
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Coronary Arteriosclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Coronary Arteriosclerosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Coronary Arteriosclerosis Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Coronary Arteriosclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 15
Coronary Arteriosclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Coronary Arteriosclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 18
Coronary Arteriosclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Coronary Arteriosclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Coronary Arteriosclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
GlobalData Methodology 82

Read the full report:
Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/703975/Coronary-Arteriosclerosis-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Cloud-based disaster recovery is critical to any production environment and is a high priority for many enterprise organizations today. Nearly 40% of organizations have had to execute their BCDR plan due to a service disruption in the past two years. Zerto on IBM Cloud offer VMware and Microsoft customers simple, automated recovery of on-premise VMware and Microsoft workloads to IBM Cloud data centers.
Why Federal cloud? What is in Federal Clouds and integrations? This session will identify the process and the FedRAMP initiative. But is it sufficient? What is the remedy for keeping abreast of cutting-edge technology? In his session at 21st Cloud Expo, Rasananda Behera will examine the proposed solutions: Private or public or hybrid cloud Responsible governing bodies How can we accomplish?
Real IoT production deployments running at scale are collecting sensor data from hundreds / thousands / millions of devices. The goal is to take business-critical actions on the real-time data and find insights from stored datasets. In his session at @ThingsExpo, John Walicki, Watson IoT Developer Advocate at IBM Cloud, will provide a fast-paced developer journey that follows the IoT sensor data from generation, to edge gateway, to edge analytics, to encryption, to the IBM Bluemix cloud, to Wa...
With the rise of DevOps, containers are at the brink of becoming a pervasive technology in Enterprise IT to accelerate application delivery for the business. When it comes to adopting containers in the enterprise, security is the highest adoption barrier. Is your organization ready to address the security risks with containers for your DevOps environment? In his session at @DevOpsSummit at 21st Cloud Expo, Chris Van Tuin, Chief Technologist, NA West at Red Hat, will discuss: The top security r...
SYS-CON Events announced today that Massive Networks, that helps your business operate seamlessly with fast, reliable, and secure internet and network solutions, has been named "Exhibitor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. As a premier telecommunications provider, Massive Networks is headquartered out of Louisville, Colorado. With years of experience under their belt, their team of...
Many companies start their journey to the cloud in the DevOps environment, where software engineers want self-service access to the custom tools and frameworks they need. Machine learning technology can help IT departments keep up with these demands. In his session at 21st Cloud Expo, Ajay Gulati, Co-Founder, CTO and Board Member at ZeroStack, will discuss the use of machine learning for automating provisioning of DevOps resources, taking the burden off IT teams.
SYS-CON Events announced today that Nihon Micron will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Nihon Micron Co., Ltd. strives for technological innovation to establish high-density, high-precision processing technology for providing printed circuit board and metal mount RFID tags used for communication devices. For more inf...
SYS-CON Events announced today that mruby Forum will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. mruby is the lightweight implementation of the Ruby language. We introduce mruby and the mruby IoT framework that enhances development productivity. For more information, visit http://forum.mruby.org/.
In his session at @ThingsExpo, Greg Gorman is the Director, IoT Developer Ecosystem, Watson IoT, will provide a short tutorial on Node-RED, a Node.js-based programming tool for wiring together hardware devices, APIs and online services in new and interesting ways. It provides a browser-based editor that makes it easy to wire together flows using a wide range of nodes in the palette that can be deployed to its runtime in a single-click. There is a large library of contributed nodes that help so...
SYS-CON Events announced today that Ryobi Systems will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Ryobi Systems Co., Ltd., as an information service company, specialized in business support for local governments and medical industry. We are challenging to achive the precision farming with AI. For more information, visit http:...
SYS-CON Events announced today that SIGMA Corporation will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. uLaser flow inspection device from the Japanese top share to Global Standard! Then, make the best use of data to flip to next page. For more information, visit http://www.sigma-k.co.jp/en/.
SYS-CON Events announced today that Daiya Industry will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Daiya Industry specializes in orthotic support systems and assistive devices with pneumatic artificial muscles in order to contribute to an extended healthy life expectancy. For more information, please visit https://www.daiyak...
Today traditional IT approaches leverage well-architected compute/networking domains to control what applications can access what data, and how. DevOps includes rapid application development/deployment leveraging concepts like containerization, third-party sourced applications and databases. Such applications need access to production data for its test and iteration cycles. Data Security? That sounds like a roadblock to DevOps vs. protecting the crown jewels to those in IT.
SYS-CON Events announced today that B2Cloud will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. B2Cloud specializes in IoT devices for preventive and predictive maintenance in any kind of equipment retrieving data like Energy consumption, working time, temperature, humidity, pressure, etc.
Automation is enabling enterprises to design, deploy, and manage more complex, hybrid cloud environments. Yet the people who manage these environments must be trained in and understanding these environments better than ever before. A new era of analytics and cognitive computing is adding intelligence, but also more complexity, to these cloud environments. How smart is your cloud? How smart should it be? In this power panel at 20th Cloud Expo, moderated by Conference Chair Roger Strukhoff, paneli...